middle.news
How Argent BioPharma’s AusCann Acquisition Could Reshape Its Global Ambitions
9:44am on Tuesday 19th of August, 2025 AEST
•
Healthcare
Read Story
How Argent BioPharma’s AusCann Acquisition Could Reshape Its Global Ambitions
9:44am on Tuesday 19th of August, 2025 AEST
Key Points
Binding term sheet to acquire AusCann’s Neuvis® drug delivery platform and related IP
Includes FDA-facing epilepsy pre-clinical data and EU-GMP manufacturing access
Acquisition valued at USD 15 million via 25 million Argent shares, pending shareholder approval
Strategic expansion of clinical pipeline and European commercial footprint
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RGT
OPEN ARTICLE